- Tristel is pleased with progress made in its strong first half, in particular with the growth seen in sales of its products used to disinfect non & single lumened instruments, hospital surfaces and within aseptic units.

Following a better than expected December, revenue will be in excess of £6.4m (2012 £4.4m) and pre-tax profit in excess of £0.7m (2012 adjusted pre-tax loss of £0.6m) exceeding levels indicated in the AGM trading update issued in December.

"We continue to build upon these successes with confidence that they will continue into the second half and beyond," said CEO Paul Swinney in a statement. Tristel, the manufacturer of infection prevention, contamination control and hygiene products, expected to report encouraging performances from all business segments.

The company has benefited from strong operational cashflow in the first half of the year and net cash at 31 December was £1.4m (2012 net debt of £0.4m).

Story provided by